InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin ...

The agreement provides up to $100 million upfront/near-term and up to ~$3.25 billion in milestones, plus single-digit tiered royalties, reflecting high optionality typical of early discovery ...

Yale University and a seasoned life science entrepreneur with over 17 years of experience building, investing in, and scaling biotechnology startups. He founded the company in 2018, originally spun ...

A key factor of this is the growing acceptance of RWD in trial design. The agency hopes that by allowing RWD collected by qualified research institutions, drug developers will not only be able to move ...

Drug-delivery failures — not flawed science — are the hidden driver of late-stage trial failures. The long, complex process that it takes to successfully bring a drug to market is one of the biggest ...

FDA authorization is underpinned by four global Phase III QWINT studies showing non-inferior A1C lowering versus glargine ...

EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business ...

A key factor of this is the growing acceptance of RWD in trial design. The agency hopes that by allowing RWD collected by qualified research institutions, drug developers will not only be able to move ...

Jen leads EVERSANA’s market access, pricing, and reimbursement strategies, helping life sciences innovators overcome barriers to drug access and affordability. With more than two decades of leadership ...

How to help drug manufacturers navigate complex market factors to reach more patients is a challenge nearly every company faces. That’s why market access strategies continue to be top of mind in the ...

Clinical data harmonization is the real bottleneck standing between life sciences companies and AI's transformative potential. The life sciences industry is navigating a pivotal transition in 2026.

Novo is open to considering a direct listing of its shares on the New York Stock Exchange, chief executive officer Mike Doustdar told the Financial Times. The shift to listing shares directly would ...